Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1977 Feb 12;1(6058):425–428. doi: 10.1136/bmj.1.6058.425

Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.

K J Willis, D R London, H W Ward, W R Butt, S S Lynch, B T Rudd
PMCID: PMC1604811  PMID: 837137

Abstract

Forty-five post-menopausal women with recurrent breast cancer were treated with the antioestrogen, tamoxifen, 20 mg twice daily. Clinical assessment after 12 weeks indicated that 18 (40%) showed some remission. Gonadotrophins were suppressed within two weeks to relatively constant concentrations within the post-menopausal range, responses to luteinising hormone-releasing hormone (LH-RH) did not change, and androgen concentrations remained within the normal range in all patients. Oestradiol concentrations rose steadily only in women in whom treatment failed. Serum prolactin concentrations were raised in 18 out of the 44 (41%) patients in whom they were measured; 13 of these did not respond to treatment. Treatment did not change the average prolactin concentration when this was within the normal range, but it significantly reduced prolactin concentrations in hyperprolactinaemic patients--within two weeks (P less than 0-01) in those who responded well and by six weeks (P less than 0-05) in those who showed no remission. Among patients with normal prolactin values the release of prolactin after thyrotrophin-releasing hormone was significantly greater in those with no remission than in those who responded to tamoxifen. Responses in those with hyperprolactinaemia were reduced to about half the control values, and again this change occurred faster in those who were successfully treated. Patients therefore seem to have a better chance of responding to anti-oestrogen treatment if prolactin secretion is low.

Full text

PDF
425

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ATKINS H. J., FALCONER M. A., HAYWARD J. L., MACLEAN K. S., SCHURR P. H., ARMITAGE P. Adrenalectomy and hypophysectomy for advanced cancer of the breast. Lancet. 1960 May 28;1(7135):1148–1153. doi: 10.1016/s0140-6736(60)91039-4. [DOI] [PubMed] [Google Scholar]
  2. Atkins H., Bulbrook R. D., Falconer M. A., Hayward J. L., MacLean K. C., Schurr P. H. Urinary steroids in the prediction of response to adrenalectomy or hypophysectomy. A second clinical trial. Lancet. 1968 Dec 14;2(7581):1261–1263. doi: 10.1016/s0140-6736(68)91758-3. [DOI] [PubMed] [Google Scholar]
  3. BULBROOK R. D., GREENWOOD F. C., HAYWARD J. L. Selection of breast-cancer patients for adrenalectomy or hypophysectomy by determination of urinary 17-hydroxycorticosteroids and aetiocholanolone. Lancet. 1960 May 28;1(7135):1154–1157. doi: 10.1016/s0140-6736(60)91040-0. [DOI] [PubMed] [Google Scholar]
  4. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Czygan P. J., Schulz K. D. Studies on the anti-oestrogenic and oestrogen-like action of clomiphene citrate in women. Gynecol Invest. 1972;3(1):126–134. doi: 10.1159/000301749. [DOI] [PubMed] [Google Scholar]
  6. Duignan N. M., Shaw R. W., Rudd B. T., Holder G., Williams J. W., Butt W. R., Logan-Edwards R., London D. R. Sex hormone levels and gonadotrophin release in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1975 May;4(3):287–295. doi: 10.1111/j.1365-2265.1975.tb01536.x. [DOI] [PubMed] [Google Scholar]
  7. Glass M. R., Williams J. W., Butt W. R., Edwards R. L., London D. R. Basal serum prolactin values and responses to the administration of thyrotrophin releasing hormone (TRH) in women with amenorrhoea. Br J Obstet Gynaecol. 1976 Jun;83(6):495–501. doi: 10.1111/j.1471-0528.1976.tb00872.x. [DOI] [PubMed] [Google Scholar]
  8. Golder M. P., Phillips M. E., Fahmy D. R., Preece P. E., Jones V., Henk J. M., Griffiths K. Plasma hormones in patients with advanced breast cancer treated with tamoxifen. Eur J Cancer. 1976 Sep;12(9):719–723. doi: 10.1016/0014-2964(76)90022-0. [DOI] [PubMed] [Google Scholar]
  9. HUGGINS C., BERGENSTAL D. M. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 1952 Feb;12(2):134–141. [PubMed] [Google Scholar]
  10. Harper M. J., Walpole A. L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature. 1966 Oct 1;212(5057):87–87. doi: 10.1038/212087a0. [DOI] [PubMed] [Google Scholar]
  11. Lunan C. B., Klopper A. Antioestrogens. A review. Clin Endocrinol (Oxf) 1975 Sep;4(5):551–572. doi: 10.1111/j.1365-2265.1975.tb01568.x. [DOI] [PubMed] [Google Scholar]
  12. Metcalf M. G. The breast cancer discriminant: effect of age, obesity, hirsutism, starvation, and changes in adrenocortical and gonadal activity. J Endocrinol. 1974 Nov;63(2):263–274. doi: 10.1677/joe.0.0630263. [DOI] [PubMed] [Google Scholar]
  13. Miller W. R., Forrest A. P. Oestradiol synthesis by a human breast carcinoma. Lancet. 1974 Oct 12;2(7885):866–868. doi: 10.1016/s0140-6736(74)91202-1. [DOI] [PubMed] [Google Scholar]
  14. Ohgo S., Kato Y., Chihara K., Imura H. Plasma prolactin responses to thyrotropin-releasing hormone in patients with breast cancer. Cancer. 1976 Mar;37(3):1412–1416. doi: 10.1002/1097-0142(197603)37:3<1412::aid-cncr2820370323>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  15. PEARSON O. H., RAY B. S. Results of hypophysectomy in the treatment of metastatic mammary carcinoma. Cancer. 1959 Jan-Feb;12(1):85–92. doi: 10.1002/1097-0142(195901/02)12:1<85::aid-cncr2820120114>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  16. Toft D., Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci U S A. 1966 Jun;55(6):1574–1581. doi: 10.1073/pnas.55.6.1574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Vekemans M., Robyn C. Influence of age on serum prolactin levels in women and men. Br Med J. 1975 Dec 27;4(5999):738–739. doi: 10.1136/bmj.4.5999.738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ward H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973 Jan 6;1(5844):13–14. doi: 10.1136/bmj.1.5844.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wilson R. G., Buchan R., Roberts M. M., Forrest A. P., Boyns A. R., Cole E. N., Griffiths K. Plasma prolactin and breast cancer. Cancer. 1974 May;33(5):1325–1327. doi: 10.1002/1097-0142(197405)33:5<1325::aid-cncr2820330517>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES